Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18520288 | 0.88 | ALDH1A1 (0.40) | PLA2G7ALDH1A1MAPTNPC1CYP1A2 | |
| SCHEMBL18520594 | 0.88 | ALDH1A1 (0.40) | PLA2G7ALDH1A1MAPTNPC1CYP1A2 | |
| SCHEMBL18520289 | 0.87 | CCNB2 (0.42) | PLA2G7ALDH1A1MAPTNPC1CYP1A2 | |
| SCHEMBL18520513 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MAPTNPC1CYP1A2CYP3A4 | |
| SCHEMBL18520511 | 0.83 | PDE2A (0.37) | ALDH1A1MAPTNPC1CYP1A2CYP3A4 | |
| SCHEMBL18520588 | 0.83 | GRM2 (0.54) | NQO2CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL18520586 | 0.83 | CDC7 (0.41) | ALDH1A1MAPTNPC1CYP1A2CYP3A4 | |
| SCHEMBL18520373 | 0.83 | CCNB2 (0.37) | ALDH1A1MAPTNPC1CYP1A2CYP3A4 | |
| SCHEMBL18520299 | 0.82 | KMT2A (0.43) | ALDH1A1MAPTCCNB2CDK1CDK4 | |
| SCHEMBL18520682 | 0.82 | CCNB2 (0.36) | ALDH1A1MAPTNPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2017027768-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | BACE1 1506/4885ADORA2A 2816/4885ADORA2B 3101/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | BACE1 1506/4885ADORA2A 2816/4885ADORA2B 3101/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | BACE1 1506/4885ADORA2A 2816/4885ADORA2B 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.